Kyverna Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-	-60.37	-28.89	-26.35
Depreciation & Amortization	-	3.43	2.46	1.42
Share-Based Compensation	-	2.22	0.93	0.25
Other Operating Activities	-	2.31	-10.61	2.53
Operating Cash Flow	-	-52.41	-36.11	-22.16
Capital Expenditures	-	-0.62	-0.77	-1.29
Change in Investments	-	-8.16	-13.33	0
Investing Cash Flow	-	-8.79	-14.1	-1.29
Share Issuance / Repurchase	-	0.65	0.18	0.03
Debt Issued / Paid	-	-0.78	-0.25	-0.04
Other Financing Activities	-	58.25	11.95	72.53
Financing Cash Flow	-	58.12	11.88	72.52
Net Cash Flow	-	-3.08	-38.33	49.08
Free Cash Flow	-	-53.03	-36.88	-23.44
Free Cash Flow Margin	-	-	-525.00%	-414.50%
Free Cash Flow Per Share	-	-78.72	-80.97	-88.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).